doi: 10.3389/fphar.2023.1155271 Received 31 January 2023 Accepted 19 April 2023 Published 05 May 2023 Volume 14 - 2023 Edited by Andresa Heemann Betti, Feevale University, Brazil Reviewed by Lekha Sleno, Universit du Qubec Montral, Canada Toby James Athersuch, Imperial College London, United Kingdom Updates Copyright 2023 Quints, Castell and Moreno-Torres
However, the paper did not show that tirzepatide was not safe and, as with many studies, limitations to the research did occur, Kirkpatrick told Healthline
This ensures its biological identity and function are exactly what you expect
Early phase trials suggest retatrutide may produce weight loss exceeding tirzepatide, though long-term safety and tolerability data remain limited